The objective of this double-masked, multicenter placebo controlled clinical trial funded by the National Eye Institute of the NIH is to evaluate whether or not prolonged suppressive oral antiviral treatment with valacyclovir 1000mg/daily reduces complications of herpes zoster ophthalmicus (HZO), in immunocompetent study participants, compared to treatment with placebo and standard care without prolonged systemic antiviral treatment, thereby improving the outcomes in this common and potentially vision and life-threatening disease.

For eligibility, study participants must be diagnosed with HZO in one eye based on both of these criteria:

• History of characteristic unilateral vesicular rash in the dermatomal distribution of cranial nerve V1.

• Medical record documentation of an episode of active dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to HZO within the preceding year.

Baylor College of Medicine is a participating clinical center for ZEDS.

Principal Investigator: Dr. Alice Matoba


April Leger april.leger@bcm.eduPhone 1: (713) 798-4123
IRB: h-41129




Oct 09, 2017